We are a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology that are intended to efficiently deliver improved cancer treatments. We have deep experience in chemistry, formulation, and drug delivery, as well as research, clinical, and commercial pharmaceutical development, resulting in successfully taking product candidates from the clinic to…
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$0.00
▼ -72.5% YoY
Net Income (TTM)
-$80M
▲ +67.7% YoY
Op. Margin
-1601.12%
▼ -1341.5pp YoY
ROIC
-45.89%
▼ -28.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$69M
▼ -60.1% YoY
Op. Cash Flow (TTM)
-$69M
▼ -63.6% YoY
Net Debt
-$190M
Net Cash Position
Cash & Equiv.
$190M
5Y CAGR: -12.6%
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with WHWK
Held by ETFs
WHWK is in 1 US ETF. The largest of them, with WHWK's weight in each:
Whitehawk Therapeutics (WHWK) in three numbers
Questions about Whitehawk Therapeutics
Is Whitehawk Therapeutics a high-quality business?
Whitehawk Therapeutics scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 5 checks computed from SEC filings. Its best check is net debt at -$190M, and its weakest is return on capital at -45.9%. The Quality tab shows every check against its target.
Does Whitehawk Therapeutics (WHWK) pay a dividend?
No. Whitehawk Therapeutics (WHWK) does not currently pay a dividend. The last payment in our data was in 2021, and nothing has been paid since. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 3 Aug 2026 (period ending 30 Jun 2026), SEC. Price: last close 4 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in WHWK's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing WHWK
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.